Search

Bio-Techne Corp

Suletud

SektorTervishoid

72.3 0.58

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

71.89

Max

72.3

Põhinäitajad

By Trading Economics

Sissetulek

13M

51M

Müük

16M

311M

P/E

Sektori keskmine

103.057

68.51

Aktsiakasum

0.53

Dividenditootlus

0.44

Kasumimarginaal

16.392

Töötajad

3,100

EBITDA

21M

99M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-1.4% downside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.44%

2.29%

Järgmine tulemuste avaldamine

12. aug 2026

Järgmine dividendimakse kuupäev

28. aug 2026

Turustatistika

By TradingEconomics

Turukapital

2.7B

11B

Eelmine avamishind

71.72

Eelmine sulgemishind

72.3

Bio-Techne Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. aug 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4. aug 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3. aug 2026, 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31. juuli 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30. juuli 2026, 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29. juuli 2026, 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20. juuli 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Võrdlus sarnastega

Hinnamuutus

Bio-Techne Corp Prognoos

Hinnasiht

By TipRanks

-1.4% langus

12 kuu keskmine prognoos

Keskmine 70.89 USD  -1.4%

Kõrge 73 USD

Madal 62 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Bio-Techne Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

11 ratings

1

Osta

10

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat